Supplementary Materials and Methods from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.22429342

2023-01-01

Abstract:Supplementary Materials and Methods

What problem does this paper attempt to address?

Supplementary Table S1-4 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.22429336

2023-01-01

Abstract:Supplementary Table S1. Clinical characteristics of 84 ICC patients depending on ALKBH5 expression levels. Supplementary Table S2. Clinical characteristics of 6 ICC specimens receiving immunotherapy. Supplementary Table S3: m6A-seq identified m6A peaks on PD-L1 mRNA. m6A peaks on PD-L1 mRNA and its corresponding primers for quantitative RT-PCR. Supplementary Table S4. m6A peaks in PD-L1 mRNA in m6A-Seq data from GSE87515.
Supplementary Table S5-11 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.22429330

2023-01-01

Abstract:Supplementary Table S5. RNA-seq: Significant DEGs (differentially expressed genes) with log|foldchange| > 1 and p-value <0.05. Supplementary Table S6. m6A-seq: RBE- shALKBH5 peaks related genes. Supplementary Table S7. m6A-seq: RBE- shCtrl peaks related genes. Supplementary Table S8. m6A-seq: RBE-shALKBH5 unique peaks related genes. Supplementary Table S9. m6A-seq: RBE-shCtrl unique peaks related genes. Supplementary Table S10. m6A-seq: common differential peaks related genes Supplementary Table S11. RNA-seq: log2normalized_count.
Supplementary Fig. S1-13 from M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.22429351

2023-01-01

Abstract:Supplementary Fig. S1. PD-L1 was regulated by ALKBH5 independent on FTO, METTL3 or METTL14. Supplementary Fig. S2. m6A-seq and mRNA-seq of RBE-shCtrl/shALKBH5 cells. Supplementary Fig. S3. Transient ALKBH5 and its mutant H204A overexpression increased the endogenous ALKBH5 protein level. Supplementary Fig. S4. ALKBH5 deficiency accelerates the degradation of PD-L1 mRNA dependent on YTHDF2. Supplementary Fig. S5. The role of YTHDF2 in regulating PD-L1 expression. Supplementary Fig. S6. Tumor cell intrinsic ALKBH5 facilitates tumor resistance to anti-tumor T cell immunity. Supplementary Fig. S7. T cell expansion was inhibited by tumor-intrinsic ALKBH5. Supplementary Fig. S8. The role of ALKBH5 in the proliferation and migration of ICC cell in vitro. Supplementary Fig. S9. PD-L1 is essential for ALKBH5-regulated anti-tumor T cell immunity. Supplementary Fig. S10. The correlation between ALKBH5 and PD-L1 transcripts in TCGA datasets. Supplementary Fig. S11. ALKBH5 positively correlates with PD-L1 expression in clinical ICC specimens. Supplementary Fig. S12. The role of ALKBH5 in ICC immune microenvironment. Supplementary Fig. S13. ALKBH5 deficiency in ICC cells relates to immunosuppressive microenvironment.
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Xinyao Qiu,Shuai Yang,Shan Wang,Jianmin Wu,Bo Zheng,Kaiting Wang,Siyun Shen,Seogsong Jeong,Zhixuan Li,Yanjing Zhu,Tong Wu,Xuan Wu,Rui Wu,Weiwei Liu,Hong-Yang Wang,Lei Chen

DOI: https://doi.org/10.1158/0008-5472.can-21-0468

IF: 11.2

2021-07-23

Cancer Research

Abstract:Abstract N6-methyladenosine (m6A) has been reported as an important mechanism of posttranscriptional regulation. Programmed death-ligand 1 (PD-L1) is a primary immune inhibitory molecule expressed on tumor cells that promotes immune evasion. Here we report ALKBH5 as an important m6A demethylase that orchestrates PD-L1 expression in intrahepatic cholangiocarcinoma (ICC). Regulation of PD-L1 expression by ALKBH5 was confirmed in human ICC cell lines. Sequencing of the m6A methylome identified PD-L1 mRNA as a direct target of m6A modification whose levels were regulated by ALKBH5. Furthermore, ALKBH5 and PD-L1 mRNA were shown to interact. ALKBH5 deficiency enriched m6A modification in the 3′UTR region of PD-L1 mRNA, thereby promoting its degradation in a YTHDF2-dependent manner. In vitro and in vivo, tumor-intrinsic ALKBH5 inhibited the expansion and cytotoxicity of T cells by sustaining tumor cell PD-L1 expression. The ALKBH5-PD-L1–regulating axis was further confirmed in human ICC specimens. Single-cell mass cytometry analysis unveiled a complex role of ALKBH5 in the tumor immune microenvironment by promoting the expression of PD-L1 on monocytes/macrophages and decreasing the infiltration of myeloid-derived suppressor-like cells. Analysis of specimens from patients receiving anti-PD1 immunotherapy suggested that tumors with strong nuclear expression patterns of ALKBH5 are more sensitive to anti-PD1 immunotherapy. Collectively, these results describe a new regulatory mechanism of PD-L1 by mRNA epigenetic modification by ALKBH5 and the potential role of ALKBH5 in immunotherapy response, which might provide insights for cancer immunotherapies. Significance: This study identifies PD-L1 mRNA as a target of ALKBH5 and reveals a role for ALKBH5 in regulating the tumor immune microenvironment and immunotherapy efficacy.

oncology
Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422753

2023-01-01

Abstract:Supplementary Methods for Xie et al, MEK inhibition modulates cytokine response to mediate therapeutic efficacy in lung cancer
AASLD Abstracts 220-442

Fanyin Meng,Chiara Braconi,Lyudmila Khrapenko,Tushar Patel,Alphonse E. Sirica,Zichen Zhang,Deanna J. Campbell,Shuit‐Tong Lee,Coral Ho,Xin Chen,Chang Han,William C. Bowen,George K. Michalopoulos,Tong Wu,Mike A. Leonis,Angela M. Longmeier,Jeremy Gibson,Susan E. Waltz,Natalia Pediconi,Stefania Vossio,Valeria Schinzari,Teresa Pollicino,Giuseppe Montalto,Melchiorre Cervello,Giovanni Raimondo,Massimo Levrero,Karin E. R. Gooijert,Rick Havinga,Henk Wolters,Renxue Wang,Victor Ling,Susumu Tazuma,Henkjan J. Verkade

DOI: https://doi.org/10.1002/hep.22641

IF: 17.298

2008-01-01

Hepatology

Abstract:Background: Autocrine expression of Interleukin-6 (IL-6) contributes to cholangiocarcinoma growth.IL-6 can modulate the expression of miRNA involved in tumor growth, and can also alter the expression of DNA methyltransferase 1 (DNMT-1).Alterations in DNMT-1 can epigenetically regulate the expression of tumor suppressor genes.Thus, our aim was to evaluate the role of IL-6 dependent miRNA on modulation of DNMT-1 and tumor suppressor gene expression in cholangiocarcinoma.Methods: Mz-ChA-1, KMCH-1, TFK-1 malignant and H69 nonmalignant cholangiocytes were used.Tumor cells were stably transfected to over-express IL-6.miRNA profiling was performed using a microarray and the expression of selected mature miRNA verified using real-time PCR.Luciferase reporter constructs were used to assess direct effects of miRNA at sites on DNMT-1 3'-UTR.Precursors to miRNA were used to enhance cellular expression.miRNA target prediction was performed using PicTar and Miranda databases.DNMT-1, p16INK4A and Rassf1a expression were assessed by western blot analysis.Results: miR-148a, miR-152 and miR-301 have sequence complementarity to the 3'-UTR of DNMT-1.Relative to non-malignant H69 cells, expression of miR-148a, miR-152 and miR-301 was decreased in Mz-ChA-1 cells by 0.25 ± 0.03-fold, 0.23 ± 0.02fold, and 0.07 ± 0.01-fold.Similar changes were noted in KMCH-1 and TFK cells.Expression of both miR-148a and miR-152 was decreased in IL-6 over-expressing tumor cells compared to controls in vitro (miR-148a: 0.2 ± 0.1-fold; miR-152: 0.1 ± 0.1-fold) and in tumor cell xenografts in vivo (miR-148a: 0.6 ± 0.1-fold; miR-152: 0.6 ± 0.1-fold).There was a concomitant decrease in several methylation-sensitive tumor suppressor genes including Rassf1a, and p16INK4a.DNMT-1 was verified as a direct target for miR-148a and miR-152.miR-148a decreased DNMT-1 expression by 75 ± 2% in Mz-ChA-1 and 62 ± 9% in KMCH-1 cells, and reduced cell proliferation in both cell lines.miR-152 also reduced prolfieration and decreased DNMT-1 expression by 58 ± 6 % and 62 ± 9% in Mz-ChA-1 and KMCH-1 cells respectively.Enforced expression of either miR-148a or miR-152 also increased expression of Rassf1a and p16INK4a activation.Summary and Conclusions: We report for the first time that IL-6 can (a) regulate DNMT1 expression by modulation of microRNAs miR-148a and miR-152, and (b) alter the expression of methylation dependent tumor suppressor genes Rassf1a and p16INK4a.These studies provide a direct link between IL-6 and epigenetic regulation of oncogenic pathways and justify targeting IL-6 for the prevention or treatment of cholangiocarcinoma.
Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964576.v1

2024-01-01

Abstract:Supplementary materials and methods
IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Man Liu,Jingying Zhou,Xiaoyu Liu,Yuanming Feng,Weiqin Yang,Feng Wu,Otto Ka-Wing Cheung,Hanyong Sun,Xuezhen Zeng,WM Tang,Myth Tsz Shun Mok,John Wong,Philip Chun Yeung,Paul B. S. Lai,Zhiwei Chen,Hongchuan Jin,Jie Chen,Stephen L. Chan,Anthony Wing‐Hung Chan,Ka Fai To,Joseph J.Y. Sung,Minhu Chen,Alfred Sze‐Lok Cheng

DOI: https://doi.org/10.1136/gutjnl-2019-iddfabstracts.4

2019-01-01

Abstract:Background Hepatocellular carcinoma (HCC), mostly developed in fibrotic/cirrhotic liver, exhibits relatively low responsiveness to immune-checkpoint blockade (ICB) therapy. As myeloid-derived suppressor cell (MDSC) is pivotal for immunosuppression, we investigated its role and regulation in the fibrotic microenvironment with an aim of developing mechanism-based combination immunotherapy. Methods Functional significance of MDSCs was evaluated by flow cytometry using two orthotopic HCC models in fibrotic liver setting via carbon tetrachloride or high-fat high-carbohydrate diet, and verified by clinical specimens. Mechanistic studies were conducted in the human hepatic stellate cell (HSC)-peripheral blood mononuclear cell culture systems and fibrotic-HCC patient-derived MDSCs. The efficacy of single or combined therapy with anti-programmed death-1-ligand-1 (anti-PD-L1) and a clinically-trialed BET bromodomain inhibitor i-BET762 was determined. Results Accumulation of monocytic MDSCs (M-MDSCs), but not polymorphonuclear MDSCs, in fibrotic livers significantly correlated with reduced tumor-infiltrating lymphocytes (TILs) and increased tumorigenicity in both mouse models. In human HCCs, the tumor-surrounding fibrotic livers were markedly enriched with M-MDSC, with its surrogate marker CD33 significantly associated with aggressive tumor phenotypes and poor survival rates. Mechanistically, activated HSCs induced monocyte-intrinsic p38 MAPK signaling to trigger enhancer reprogramming for M-MDSC development and immunosuppression. Treatment with p38 MAPK inhibitor abrogated HSC-M-MDSC crosstalk to prevent HCC growth. Concomitant with patient-derived M-MDSC suppression by i-BET762, combined treatment with anti-PD-L1 synergistically enhanced TILs, resulting in tumor eradication and prolonged survival in the fibrotic-HCC mouse model. Conclusions Our results signify how non-tumor intrinsic properties in the desmoplastic microenvironment can be exploited to reinstate immunosurveillance, providing readily translatable combination strategies to empower HCC immunotherapy (figure 1). Acknowledgement This project is supported by the University Grants Committee through the Collaborative Research Fund (C4045–18W) and the Theme-based Research Scheme (T11–706/18-N), the Health and Medical Research Fund (16170451), the Terry Fox Foundation, the Focused Innovations Scheme-Scheme B (1907309) from the Chinese University of Hong Kong and the Li Ka Shing Foundation (Canada). Man Liu is supported by China Postdoctoral Science Foundation.
Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Yufei Wang,Man Zhao,Lina Zhao,Yu Geng,Guanghao Li,Lin Chen,Jingxuan Yu,Hongfeng Yuan,Huihui Zhang,Haolin Yun,Ying Yuan,Guowen Wang,Jinyan Feng,Liang Xu,Shuai Wang,Chunyu Hou,Guang Yang,Ningning Zhang,Wei Lu,Xiaodong Zhang

DOI: https://doi.org/10.1158/0008-5472.22433561.v1

2023-01-01

Abstract:Supplementary materials and methods, Supplementary figures, Supplementary figure legends, Supplementary tables
Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Cuicui Liu,Jiankun Qiang,Qiaodan Deng,Jie Xia,Lu Deng,Lei Zhou,Dong Wang,Xueyan He,Ying Liu,Botao Zhao,Jinhui Lv,Zuoren Yu,Qun-Ying Lei,Zhi-Ming Shao,Xiao-Yong Zhang,Lixing Zhang,Suling Liu

DOI: https://doi.org/10.1158/0008-5472.22429821.v1

2023-01-01

Abstract:Supplementary Methods, Figures and Figure legends
Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Jiang Chen,Zohreh Amoozgar,Xin Liu,Shuichi Aoki,Zelong Liu,Sarah M. Shin,Aya Matsui,Alexei Hernandez,Zhangya Pu,Stefan Halvorsen,Pin-Ji Lei,Meenal Datta,Lingling Zhu,Zhiping Ruan,Lei Shi,Daniel Staiculescu,Koetsu Inoue,Lance L. Munn,Dai Fukumura,Peigen Huang,Slim Sassi,Nabeel Bardeesy,Won Jin Ho,Rakesh K. Jain,Dan G. Duda

DOI: https://doi.org/10.1158/2326-6066.25523060.v1

2024-01-01

Abstract:Supplementary Table S3: IMC panel.
Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Peixiang Lu,Ge Chen,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395141

2023-01-01

Abstract:PDF file - 47K, Sequences of primers used in this study
Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Alfred S.L. Cheng,Suki S. Lau,Yangchao Chen,Yutaka Kondo,May S. Li,Hai Feng,Arthur K. Ching,Kin F. Cheung,Hoi K. Wong,Joanna H. Tong,Hongchuan Jin,Kwong W. Choy,Jun Yu,Ka F. To,Nathalie Wong,Tim H.-M. Huang,Joseph J.Y. Sung

DOI: https://doi.org/10.1158/0008-5472.22395239.v1

2023-01-01

Abstract:Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes β-Catenin–Dependent Hepatocarcinogenesis
Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Tao Jiang,Qiqi Jin,Jiahao Wang,Fengying Wu,Jian Chen,Gongyan Chen,Yunchao Huang,Jianhua Chen,Ying Cheng,QiMing Wang,Yueyin Pan,Jianying Zhou,Jianhua Shi,Xingxiang Xu,LiZhu Lin,Wei Zhang,Yiping Zhang,Yunpeng Liu,Yong Fang,Jifeng Feng,Zhehai Wang,Sheng Hu,Jian Fang,Yongqian Shu,Jiuwei Cui,Yi Hu,Wenxiu Yao,Xingya Li,Xiaoyan Lin,Rui Wang,Yongsheng Wang,Wei Shi,Gaohua Feng,Jun Ni,Beibei Mao,Dandan Ren,Huaibo Sun,Henghui Zhang,Luonan Chen,Caicun Zhou,Shengxiang Ren

DOI: https://doi.org/10.1158/1078-0432.23791953.v1

2023-01-01

Abstract:Supplementary Materials
Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Lixing Zhang,Hefen Sun,Fangyu Zhao,Ping Lu,Chao Ge,Hong Li,Helei Hou,Mingxia Yan,Taoyang Chen,Guoping Jiang,Haiyang Xie,Ying Cui,Xiaowu Huang,Jia Fan,Ming Yao,Jinjun Li

DOI: https://doi.org/10.1158/0008-5472.22395144.v1

2023-01-01

Abstract:PDF file - 82K, Antibodies used in this study
Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Hong Liu,Yiyang Xu,Jingyi Xiang,Li Long,Shon Green,Zhiyuan Yang,Bryan Zimdahl,Jingwei Lu,Neal Cheng,Lucas H. Horan,Bin Liu,Su Yan,Pei Wang,Juan Diaz,Lu Jin,Yoko Nakano,Javier F. Morales,Pengbo Zhang,Lian-xing Liu,Binnaz K. Staley,Saul J. Priceman,Christine E. Brown,Stephen J. Forman,Vivien W. Chan,Cheng Liu

DOI: https://doi.org/10.1158/1078-0432.22467768

2023-01-01

Abstract:Supplementary Materials and Methods
Investigation of PD-1H in DEN-induced Mouse Liver Cancer Model.

C-J Lei,B. Wang,Z-X Long,H. Ren,Q-Y Pan,Y. Li

DOI: https://doi.org/10.26355/eurrev_201808_15716

2018-01-01

European review for medical and pharmacological sciences

Abstract:OBJECTIVE:Immune therapy has recently become a novel strategy for treating liver cancer, making it of critical importance to identify novel targets for treatment. Programmed death-1 homology (PD-1H) is one newly discovered negative co-stimulating molecule, and plays important regulatory roles in suppressing T cell activation. However, the expression or function of PD-1H in liver tumors has not been reported.MATERIALS AND METHODS:Liver cancer tissues were collected from The Cancer Genome Atlas (TCGA) (http://tcga-data.nci-nih.gov). This study then utilized diethylnitrosamine (DEN) induced liver cancer mice, on which PD-1H monoclonal antibody and PD-1H extra-cellular Fc domain fusion protein were injected intraperitoneal. General status, gross morphology of liver tissues was examined, followed by hematoxylin-eosin (HE) staining and plotting survival curve.RESULTS:Among TCGA samples, PD-1H expression was significantly elevated. Induced liver cancer mice showed depressed mental status, early onset of hepatitis and liver cirrhosis. Five mice dead in model group (mortality=33.33%). No natural death occurred in control group. Injection of PD-1H-Fc-Ig fusion and PD-1H monoclonal antibody improved the condition to certain extents, with morality at about 20%. Comparing to DEN group, combined treatment group showed significantly fewer tumor lesion on liver surface, with increased body weight and lower liver-body weight ratio. HE staining showed significantly elevated ratio of normal cells in combined treatment group, although large amounts of cancer cells still existed.CONCLUSIONS:Blocking of PD-1H signal pathway could suppress liver cancer cell growth, decrease mouse mortality, indicating promising application of PD-1H in tumor immune therapy.
Immune Cell Atlas of Cholangiocarcinomas Reveals Distinct Tumor Microenvironments and Associated Prognoses.

Tao Xia,Keyu Li,Nan Niu,Yingkuan Shao,Ding,Dwayne L. Thomas,Hao Jing,Kenji Fujiwara,Haijie Hu,Arsen Osipov,Chunhui Yuan,Christopher L. Wolfgang,Elizabeth D. Thompson,Robert A. Anders,Jin He,Yiping Mou,Adrian G. Murphy,Lei Zheng

DOI: https://doi.org/10.1186/s13045-022-01253-z

IF: 28.5

2022-01-01

Journal of Hematology & Oncology

Abstract:BACKGROUND:Immunotherapy has demonstrated a limited clinical efficacy in approximately 5% of cholangiocarcinoma. The main challenges for an effective immunotherapy response in cholangiocarcinoma arise from the tumor microenvironment, which is poorly understood.METHODS:For a comprehensive analysis of the tumor microenvironment in cholangiocarcinoma, we performed multiplex immunohistochemistry with two 15-marker immune panels and Nanostring assays for a comprehensive analysis of 104 surgically resected cholangiocarcinomas including intrahepatic, hilar, and distal cholangiocarcinoma. We also validated some key findings with a batch integration analysis of published single cell RNA sequencing data.RESULTS:This study found that natural killer cells occupy the largest immune cell compartment in cholangiocarcinoma. Granzyme-B+CD8+ effector T cells are significantly associated with better overall survival in both intrahepatic and distal cholangiocarcinoma. Above 85% of intrahepatic cholangiocarcinomas with higher density of PD-1-EOMES-CD8+ effector T cells are associated with long-term survival. However, only the density of PD-1-EOMES-CD8+ T cells in the tumor areas, but not in the peripheries of the tumors, is prognostic. In all three cholangiocarcinoma subtypes, T regulator cells are significantly associated with a poor prognosis; however, M1 and M2 tumor-associated macrophages or PD-L1+ tumor-associated macrophage demonstrate different prognostic values. Combining PD-L1+ M1 or M2, PD-L1- M1 or M2 tumor-associated macrophages, and T regulator cells to subgroup intrahepatic and distal cholangiocarcinoma, the prognosis is significantly better distinguished. Moreover, PD-L1- M2 tumor-associated macrophages is associated with a good prognosis in intrahepatic and distal cholangiocarcinoma, suggesting this subtype of M2 tumor-associated macrophages may be antitumoral. Interestingly, lower densities of various types of immunosuppressive cells are associated with decreased infiltration of effector T cells in distal and hilar cholangiocarcinoma, but not in intrahepatic cholangiocarcinoma. In intrahepatic cholangiocarcinoma, PD-L1+ tumor-associated macrophages exert their immunosuppressive function likely through promoting T cell exhaustion.CONCLUSIONS:This study suggests that the densities of Granzyme-B+CD8+ effector T cells and non-exhausted PD-1-EOMES-CD8+ T cells and the PD-L1 status in the tumor-associated macrophages are prognostic makers in cholangiocarcinomas. The study also supports targeting PD-L1+ tumor-associated macrophages as the immunotherapy for cholangiocarcinoma.
Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Peng Yuan,Xiao-Hong He,Ye-Fei Rong,Jing Cao,Yong Li,Yun-Ping Hu,Yingbin Liu,Dangsheng Li,Wenhui Lou,Mo-Fang Liu

DOI: https://doi.org/10.1158/0008-5472.22413540

2023-01-01

Abstract:This file contains Materials and Methods that are involved in the figures of the main text and supplementary information. These materials and methods include information of plasmid constructs, cell transfection and viral transduction, RNA preparation and qRT-PCR, luciferase reporter assay, ChIP assay, therapeutic experiments in mice, and immunohistochemistry and in situ hybridization.
Supplementary Figure S2 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Jialei Weng,Zheng Wang,Zhiqiu Hu,Wenxin Xu,Jia-Lei Sun,Fu Wang,Qiang Zhou,Shaoqing Liu,Min Xu,Minghao Xu,Dongmei Gao,Ying-Hao Shen,Yong Yi,Yi Shi,Qiongzhu Dong,Chenhao Zhou,Ning Ren

DOI: https://doi.org/10.1158/0008-5472.25964603.v1

2024-01-01

Abstract:Representative IHC staining images of p53 protein in murine liver tumor tissues in the indicated groups. Scale bar: 50 μm.

Supplementary Materials and Methods from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Table S1-4 from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Table S5-11 from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Fig. S1-13 from M<sup>6</sup>A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Methods from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

AASLD Abstracts 220-442

Supplementary materials and methods from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Supplementary Data from HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression

Supplementary Data and Methods from ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression

Supplementary Table S3 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy

Supplementary Table 2 from BMP4 Administration Induces Differentiation of CD133<sup>+</sup> Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Methods, Figures 1-9, Tables 2-6 from EZH2-Mediated Concordant Repression of Wnt Antagonists Promotes Β-Catenin–dependent Hepatocarcinogenesis

Supplementary Data 1 from HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer

Supplementary Table 1 from BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma

Supplementary Materials and Methods from Targeting Alpha-Fetoprotein (AFP)–MHC Complex with CAR T-Cell Therapy for Liver Cancer

Investigation of PD-1H in DEN-induced Mouse Liver Cancer Model.

Immune Cell Atlas of Cholangiocarcinomas Reveals Distinct Tumor Microenvironments and Associated Prognoses.

Supplemental Materials and Methods from KRAS/NF-κB/YY1/miR-489 Signaling Axis Controls Pancreatic Cancer Metastasis

Supplementary Figure S2 from Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy

Supplementary Materials and Methods from M&lt;sup&gt;6&lt;/sup&gt;A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Table S1-4 from M&lt;sup&gt;6&lt;/sup&gt;A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Table S5-11 from M&lt;sup&gt;6&lt;/sup&gt;A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

Supplementary Fig. S1-13 from M&lt;sup&gt;6&lt;/sup&gt;A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma